China Healthwise Holdings Ltd. (HK:0348)
:0348
Top Page
China Healthwise Holdings
(0348)
Select Model
Select Model
Rating:39Underperform
Price Target:
HK$0.13
▼(-7.86% Downside)
Action:DowngradedDate:12/31/25
The score is driven primarily by very weak financial performance (declining revenue, ongoing losses, negative equity, and zero operating/free cash flow in 2024). Technical indicators also lean bearish with the price below key moving averages and negative MACD. Valuation does not offset these risks because losses drive a negative P/E and there is no dividend yield support.
Positive Factors
Market Position
China Healthwise's focus on holistic health solutions positions it well in the growing market for alternative and complementary healthcare, potentially increasing its customer base and revenue streams.
Negative Factors
Revenue Decline
Consistent revenue decline over recent years suggests challenges in maintaining market share and competitiveness, potentially impacting long-term financial health.
Read all positive and negative factors
Positive Factors
Negative Factors
Market Position
China Healthwise's focus on holistic health solutions positions it well in the growing market for alternative and complementary healthcare, potentially increasing its customer base and revenue streams.
Read all positive factors
China Healthwise Holdings (0348) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$70.88M
Dividend YieldN/A
Average Volume (3M)735.98K
Price to Earnings (P/E)19.0
Beta (1Y)1.07
Revenue Growth-17.97%
EPS Growth92.26%
CountryHK
Employees90
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding770,480,830
10 Day Avg. Volume624,920
30 Day Avg. Volume735,980
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-6.50
Price to Sales (P/S)1.05
P/FCF Ratio38.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Healthwise Holdings Business Overview & Revenue Model
Company Description
China Healthwise Holdings Limited, an investment holding company, sells Chinese health products in Hong Kong. It operates through Chinese Health Products, Money Lending Business, and Investment in Financial Instruments segments. The company sells ...
How the Company Makes Money
China Healthwise generates revenue through multiple streams, primarily from the sale of health supplements and wellness products, as well as offering traditional Chinese medicine services. The company capitalizes on its established brand reputatio...
China Healthwise Holdings Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
15
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 103.70M | 113.58M | 146.32M | 142.06M | 170.08M | 137.85M |
| Gross Profit | 34.99M | 35.00M | 60.29M | 53.27M | 90.99M | 61.06M |
| EBITDA | -9.22M | -20.07M | -117.45M | -45.80M | -89.97M | -45.33M |
| Net Income | -10.20M | -40.28M | -134.56M | -54.27M | -103.05M | -71.45M |
Balance Sheet | ||||||
| Total Assets | 110.90M | 122.05M | 149.67M | 287.66M | 314.10M | 434.28M |
| Cash, Cash Equivalents and Short-Term Investments | 47.17M | 44.72M | 54.28M | 73.02M | 96.91M | 139.92M |
| Total Debt | 107.93M | 103.74M | 108.90M | 109.90M | 90.86M | 113.81M |
| Total Liabilities | 127.86M | 140.43M | 145.27M | 149.01M | 121.03M | 137.99M |
| Stockholders Equity | -16.96M | -18.38M | 4.40M | 138.65M | 193.06M | 296.29M |
Cash Flow | ||||||
| Free Cash Flow | 5.39M | 3.12M | 14.30M | -28.97M | 41.72M | 7.47M |
| Operating Cash Flow | 5.59M | 3.38M | 14.49M | -28.34M | 42.08M | 11.99M |
| Investing Cash Flow | -200.00K | -257.00K | -191.00K | -631.00K | -360.00K | 1.50M |
| Financing Cash Flow | -6.47M | -7.84M | -17.04M | 5.95M | -36.36M | -25.75M |
China Healthwise Holdings Technical Analysis
Negative
0.14
Price Trends
0.12
Negative
0.14
Negative
0.13
Negative
Market Momentum
-0.01
Positive
8.16
Positive
25.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0348, the sentiment is Negative. The current price of 0.14 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.12, and above the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 8.16 is Positive, neither overbought nor oversold. The STOCH value of 25.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0348.
China Healthwise Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | HK$63.01M | -6.14 | -7.91% | ― | -34.73% | -4642.86% | |
56 Neutral | HK$294.15M | -13.32 | 0.86% | 5.87% | -10.78% | -82.81% | |
53 Neutral | HK$382.74M | -21.76 | -7.33% | ― | 11.32% | 62.61% | |
53 Neutral | HK$236.91M | -9.36 | -5.18% | 28.00% | -1.68% | -111.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | HK$399.07M | -1.59 | 76.98% | ― | ― | ― | |
39 Underperform | HK$70.88M | 19.02 | 57.72% | ― | -17.97% | 92.26% |
* Healthcare Sector Average
HK:0348
China Healthwise Holdings
0.09
>-0.01
-8.00%
HK:0399
Innovative Pharmaceutical Biotech
0.13
-0.03
-17.65%
HK:2700
Green International Holdings Limited
0.58
0.10
20.83%
HK:1110
Kingworld Medicines Group Ltd.
0.49
0.05
12.79%
HK:2211
Universal Health International Group Holding Ltd.
0.57
-0.41
-41.84%
HK:3390
Tycoon Group Holdings Limited
0.27
-3.19
-92.32%
China Healthwise Holdings Corporate Events
China Healthwise Subsidiary Hit by Forced Sale of Yunfeng Financial Shares to Clear Margin Debt
Jan 7, 2026
China Healthwise Holdings has disclosed that its indirect wholly owned subsidiary Future Empire Limited was subject to a forced sale of 2,646,000 shares in Yunfeng Financial Group, generating about HK$9.2 million before costs. The disposal, trigge...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.